查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1912765

恶性肿瘤动态疗法药物市场：2026-2032年全球预测（按分子类型、光源、製剂、给药途径、应用和最终用户划分）

Malignancy Photosensitizers Market by Molecule Type, Light Source, Formulation, Administration Route, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年恶性肿瘤动态疗法市值为 5.6527 亿美元，预计到 2026 年将成长至 6.1978 亿美元，年复合成长率为 11.09%，到 2032 年将达到 11.8027 亿美元。

关键市场统计数据
基准年 2025 5.6527亿美元
预计年份：2026年 6.1978亿美元
预测年份 2032 11.8027亿美元
复合年增长率 (%) 11.09%

对现代光敏剂在肿瘤学及相关专业领域应用的科学、临床和技术基础进行清晰概述

光敏剂作为标靶动态疗法和诊断影像的载体，已成为肿瘤学和皮肤病学治疗模式发展的核心。本文首先概述了光敏剂的科学基础，阐述了其透过光活化产生活性氧的作用机制，以及其在提高肿瘤切除精度和病灶可视化方面的作用。随着临床实践向微创治疗（尽可能减少对健康组织的损伤）转变，光敏剂为化学、光学和以患者为中心的治疗方案设计搭建了一座桥樑。

分子创新、整合光传输技术的进步以及不断演变的临床范式如何重塑动态学的应用格局和治疗潜力

恶性肿瘤光敏剂领域正经历着变革性的转变，这主要得益于分子工程的突破、光传输技术的创新以及不断变化的临床需求。分子支架的进步促成了具有高量子产率和可调谐吸收频谱的药物的研发，使其在与合适的光源结合时能够实现深层组织穿透。同时，从更紧凑的二极体雷射到先进的近红外线，光传输系统的改进正在拓展其在内臟恶性肿瘤和皮肤病变治疗中的应用范围。

2025年关税调整对光敏剂和光电元件供应链的采购、来源多元化和製造韧性的影响

2025年的关税和贸易政策调整已导致光敏剂系统所用原料、活性药物成分和特种光学元件的供应链经济和筹资策略发生显着变化。製造商和设备整合商正在透过重新评估供应商多元化、加快替代供应商的资格认证，以及在某些情况下调整垂直整合策略以确保关键投入品的供应来应对这些变化。这些调整对于依赖跨境供应高纯度中间体和精密光电元件的公司尤其重要。

综合細項分析揭示了分子化学、临床应用、光照方案、製剂、给药途径和最终用户环境如何决定开发路径

从多个市场细分观点进行的市场分析揭示了影响研发、监管策略和商业化的技术和临床重点。报告按分子类型重点关注氯、菁、酞菁和卟啉化学，每种化合物都具有独特的光谱和药物动力学特性，可满足特定的治疗目标。氯和卟啉通常具有强大的单线态氧生成能力，而菁骨架则可实现可调的近红外线吸​​收，有助于更深层的组织标靶化。酞菁具有优异的光稳定性，适用于可重复的临床应用。

影响光敏剂临床应用、供应策略和商业化路径的关键区域趋势和法规环境

区域趋势将显着影响临床试验的启动地点、商业伙伴关係的建立方式以及哪些治疗领域能够率先应用。在美洲，转化研究计画备受重视，这些计画将医院肿瘤中心与门诊诊所连接起来，并由密集的专科诊所网路提供支持，以便快速引入新型微创疗法。该地区的相关人员倾向于关注监管与既定路径的协调一致，以及与支付方的沟通策略，以明确报销流程和门诊治疗的整合。

分子创新者、医疗设备整合商和临床研究中心之间既竞争又合作的动态关係正在加速转化研究和商业性应用。

竞争动态正由生物製药创新公司、医疗设备製造商和学术机构组成的联合体共同塑造，他们携手推动化学、递送和临床应用的发展。领先的研究人员和产业团队正投资于独特的价值提案，涵盖从具有优化光物理特性的下一代分子支架到结合光源和用户友好介面的整合系统，这些系统均针对临床环境进行了客製化。专注于化学的开发人员与设备整合商之间的策略联盟日益普遍，这反映了高效动态疗法解决方案的跨学科需求。

领导者可采取的策略重点，以协调分子创新、供应链韧性、临床证据产生和商业模式，从而实现快速且持续的推广。

产业领导者应优先考虑整合分子设计、製剂策略和光递送解决方案，使其与实际临床工作流程相契合，从而最大限度地提高应用率。首先，应投资于转化开发，将目标化学物质与合适的光源和给药途径结合，以确保临床可行性。这包括对光敏剂和二极体雷射/LED平台进行严格的兼容性测试。其次，应建构具有韧性的供应链，对关键中间体和光电元件的多个供应商进行资格认证，并探索近岸製造伙伴关係，以降低贸易中断带来的风险。

采用透明的混合方法调查方法，结合了专家访谈、技术和临床文献分析以及方法三角验证的可靠结果。

本研究结合一手资料和二手资料，全面涵盖了光敏剂的技术、临床和商业性方面。一手资料包括对临床研究人员、医院和诊所的采购人员以及参与转化光医学的研究科学家进行的结构化访谈，并辅以与监管专家的咨询，以检验他们对核准流程的解读。二手资料分析涵盖了同行评审文献、临床试验註册资讯、专利状态以及公开的监管文件，旨在将科学进展置于特定背景下，并推算出其临床应用的时间线。

本文从综合角度探讨了跨学科协作、证据产生和营运协调如何决定临床影响和永续应用的路径。

总之，光敏剂在化学、光学和临床实践的交叉领域中占据着独特的地位，对肿瘤学、皮肤病学和眼科学具有重要意义。分子设计和光递送系统的技术进步正在拓展其临床应用范围，而不断发展的医疗模式和采购惯例正在影响着新型治疗方法在门诊和住院环境中的引入方式。整合稳健的转化流程、弹性供应链和在地化商业化策略的相关人员，将更有能力将科学进步转化为永续的临床影响。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以分子类型分類的恶性肿瘤动态疗法药物市场

  • 氯
  • 花菁
  • 酞菁
  • 卟啉

9. 依光源分類的恶性肿瘤动态疗法药物市场

  • 雷射
    • 二极体雷射
    • 气体雷射
  • LED
    • 近红外线LED
    • 可见光LED

第十章 恶性肿瘤动态疗法药物市场（依剂型划分）

  • 注射
  • 口服
  • 外用药物

第十一章 恶性肿瘤动态疗法药物市场（依给药途径划分）

  • 静脉注射
  • 口服
  • 外用

第十二章 恶性肿瘤动态疗法药物市场（依应用领域划分）

  • 皮肤科
  • 肿瘤学
    • 头颈癌
    • 内臟癌
    • 皮肤癌
  • 眼科

第十三章 恶性肿瘤动态疗法药物市场（依最终用户划分）

  • 诊所
    • 门诊部
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院
  • 研究所

第十四章 恶性肿瘤动态疗法药物市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 恶性肿瘤动态疗法药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国恶性肿瘤动态疗法药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肿瘤光动态疗法药物市场

第十八章：中国恶性肿瘤动态疗法药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bausch Health Co Ltd.
  • Biolitec Pharma GmbH
  • Endocyte, Inc.
  • Galderma SA
  • Merck KGaA
  • Photocure ASA
  • PhotoThera, Inc.
  • QLT Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Sorrento Therapeutics, Inc.
  • Zhejiang Kangyuan Biopharm Co., Ltd.
Product Code: MRR-AE420CB13A83

The Malignancy Photosensitizers Market was valued at USD 565.27 million in 2025 and is projected to grow to USD 619.78 million in 2026, with a CAGR of 11.09%, reaching USD 1,180.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 565.27 million
Estimated Year [2026] USD 619.78 million
Forecast Year [2032] USD 1,180.27 million
CAGR (%) 11.09%

A clear overview of the scientific, clinical, and technological foundations that define modern photosensitizer applications in oncology and related specialties

Malignancy photosensitizers, as agents that enable targeted photodynamic therapies and diagnostic imaging, have become central to evolving oncological and dermatological treatment paradigms. This introduction sets the stage by outlining the scientific foundations of photosensitizers, their mechanism of action in generating reactive oxygen species upon light activation, and their role in enhancing the precision of tumor ablation and lesion visualization. As clinical practice shifts toward minimally invasive options that preserve healthy tissue, photosensitizers bridge chemistry, optics, and patient-centered therapeutic design.

Moreover, recent years have seen convergence across disciplines-molecular design, formulation science, and light-delivery technologies-driving new generations of agents with improved tissue penetration, photostability, and selective uptake by malignant cells. Regulatory scrutiny and clinical validation pathways have simultaneously matured, so stakeholders face a complex interplay of translational science, safety profiling, and commercial strategy. Consequently, understanding the landscape requires both technical fluency and appreciation of clinical workflows, reimbursement dynamics, and institutional adoption patterns.

How molecular innovation, integrated light-delivery developments, and evolving clinical paradigms are reshaping adoption and therapeutic potential in photodynamic oncology

The landscape for malignancy photosensitizers is undergoing transformative shifts driven by breakthroughs in molecular engineering, light-delivery innovation, and evolving clinical expectations. Advances in molecular scaffolds have yielded agents with higher quantum yields and tunable absorption spectra, which in turn enable deeper tissue penetration when paired with appropriate light sources. Concurrently, improvements in light-delivery systems-ranging from more compact diode lasers to sophisticated near-infrared emitters-have expanded the practical envelope for treating internal organ malignancies as well as cutaneous lesions.

Equally important, translational research is emphasizing combination regimens that integrate photosensitizers with immunotherapies, targeted agents, and precision delivery mechanisms. This trend reflects an appreciation that photoactivated modalities can not only ablate tumor tissue but also modulate tumor microenvironments and augment systemic anti-tumor responses. In parallel, clinical adoption is being shaped by streamlined regulatory expectations for localized therapies and by the growing emphasis on outpatient and ambulatory care models, which favor formulations and administration routes that reduce procedural complexity and resource burden. Taken together, these shifts are redefining where and how photosensitizers are developed, tested, and deployed in clinical settings.

Impacts of 2025 tariff adjustments on procurement, supplier diversification, and manufacturing resilience for photosensitizer and optoelectronic supply chains

The imposition of tariffs and trade policy adjustments in 2025 has introduced discrete shifts in supply chain economics and sourcing strategies for raw materials, active pharmaceutical ingredients, and specialized optical components used in photosensitizer systems. Manufacturers and device integrators are responding by reassessing supplier diversification, accelerating qualification of alternative suppliers, and in some cases adjusting vertical integration strategies to secure critical inputs. These adjustments are particularly relevant for firms that rely on cross-border supply of high-purity intermediates and precision optoelectronic components.

Consequently, procurement and manufacturing teams have increased emphasis on dual-sourcing, onshore contract manufacturing partnerships, and inventory optimization to mitigate exposure to tariff-driven cost volatility. At the same time, regulatory compliance and quality assurance remain non-negotiable, which means that near-shore or on-shore suppliers must meet established pharmacopoeial and device-level standards. In the medium term, organizations that invest in resilient procurement architectures and transparent supplier qualification processes are better positioned to sustain clinical programs, maintain product availability for healthcare providers, and preserve strategic flexibility amid shifting trade environments.

Integrated segmentation analysis revealing how molecule chemistry, clinical application, light-delivery choices, formulation, route, and end-user environments determine development pathways

Analyzing the market through multiple segmentation lenses reveals distinct technical and clinical priorities that influence R&D, regulatory strategy, and commercialization. Based on molecule type, attention is concentrated on Chlorin, Cyanine, Phthalocyanine, and Porphyrin chemistries, each offering unique spectral and pharmacokinetic properties that align with specific therapeutic goals. Chlorins and porphyrins typically provide robust singlet oxygen generation, while cyanine scaffolds enable tunable near-infrared absorption that supports deeper tissue targeting; phthalocyanines contribute strong photostability for repeatable clinical use.

Based on application, developers and clinicians differentiate priority pathways across Dermatology, Oncology, and Ophthalmology, with Oncology studies focusing on head and neck cancer, internal organ cancers, and skin cancer subtypes. These therapeutic contexts impose divergent requirements for delivery precision, depth of penetration, and safety profiles. Based on light source, system choice is pivotal: laser and LED platforms offer different trade-offs, where lasers-further divided into diode and gas laser types-provide coherent, high-intensity beams for focused ablation, while LEDs-further divided into near infrared LED and visible LED options-offer broader, lower-cost illumination suitable for superficial or diffuse lesions. Based on formulation, choices among injectable, oral, and topical forms dictate pharmacokinetics, patient convenience, and peri-procedural workflows. Based on administration route, intravenous, oral, and topical approaches each carry distinct clinical operational implications, from infusion suite requirements to at-home dosing feasibility. Based on end user, the spectrum ranges from clinic to hospital to research institute, with clinics differentiated into outpatient clinic and specialty clinic settings, and hospitals differentiated into private hospital and public hospital environments; these distinctions influence procurement cycles, capital equipment budgets, and staff training models. Together, these segmentation axes shape product design decisions, go-to-market strategies, and clinical development pathways, and they underscore the necessity of aligning molecular profiles with delivery systems and end-user workflows.

Regional dynamics and regulatory environments across major global regions that shape clinical adoption, supply strategies, and commercialization pathways for photosensitizers

Regional dynamics profoundly influence where clinical trials are initiated, how commercial partnerships are structured, and which therapeutic niches garner early adoption. In the Americas, there is a strong emphasis on translational pipelines that bridge hospital-based oncology centers with ambulatory clinics, supported by dense networks of specialty clinics that can rapidly adopt novel minimally invasive therapies. Stakeholders in this region frequently concentrate on regulatory alignment with established pathways and on payer engagement strategies that clarify procedural reimbursement and outpatient integration.

In Europe, Middle East & Africa, regulatory heterogeneity and varied healthcare financing models encourage localized partnership strategies and adaptive clinical development plans; consequently, manufacturers often pursue region-specific evidence generation and supply arrangements. The necessity of accommodating both advanced tertiary care centers and resource-constrained settings has also driven interest in cost-effective light-delivery solutions and stable formulations suitable for broader distribution. In Asia-Pacific, rapid expansion of oncology infrastructure, investments in clinical research capacity, and a growing focus on early-stage adoption create fertile conditions for introducing next-generation photosensitizers, particularly where local manufacturing and consortium-based clinical programs can reduce time-to-clinic. Across all regions, regional reimbursement frameworks, regulatory expectations, and institutional procurement practices remain key determinants of adoption velocity and market entry tactics.

Competitive and collaborative dynamics among molecular innovators, device integrators, and clinical research centers that accelerate translation and commercial adoption

Competitive dynamics are being defined by a mix of specialized biopharmaceutical innovators, device manufacturers, and academic spinouts that together advance chemistry, delivery, and clinical translation. Leading researchers and industry teams are investing in distinct value propositions-ranging from next-generation molecular scaffolds with optimized photophysics to integrated systems that combine tailored light sources with user-friendly interfaces for clinical settings. Strategic partnerships between chemistry-focused developers and device integrators are increasingly common, reflecting the interdisciplinary demands of effective photodynamic therapy solutions.

Additionally, research institutes and clinical centers continue to play a pivotal role in evidence generation, often collaborating with industry to refine protocols and demonstrate safety and efficacy across diverse indications. Licensing agreements, co-development arrangements, and targeted acquisitions remain viable routes for companies seeking to broaden their product portfolios or to secure proprietary delivery technologies. Importantly, organizations that can demonstrate robust clinical data, streamlined regulatory pathways, and clear operational benefits for hospitals and clinics are more likely to secure favorable collaborations and accelerate clinical uptake.

Actionable strategic priorities for leaders to align molecular innovation, supply resilience, clinical evidence generation, and commercial models for rapid and sustainable uptake

Industry leaders should prioritize an integrated approach that aligns molecular design, formulation strategy, and light-delivery solutions with pragmatic clinical workflows to maximize uptake. First, invest in translational development that pairs targeted chemistries with appropriate light sources and administration routes to ensure clinical feasibility; this includes rigorous compatibility testing between photosensitizers and both diode lasers and LED platforms. Second, build resilient supply chains by qualifying multiple suppliers for critical intermediates and optoelectronic components, and explore near-shore manufacturing partnerships that reduce exposure to trade-related disruptions.

Third, establish collaborative clinical programs that generate real-world evidence across outpatient clinics, specialty clinics, private and public hospitals, and research institutes, thereby demonstrating operational benefits and facilitating reimbursement conversations. Fourth, pursue regulatory strategies that leverage existing localized review pathways while planning for cross-region harmonization to streamline multi-jurisdiction deployment. Finally, consider flexible commercial models-such as bundled service offerings or device-as-a-service arrangements-that lower barriers to adoption for facilities with constrained capital budgets and accelerate integration into routine care.

A transparent mixed-methods research approach combining primary expert interviews, secondary technical and clinical literature analysis, and methodological triangulation for robust insights

This research synthesizes primary and secondary approaches to ensure comprehensive coverage of the technical, clinical, and commercial dimensions of photosensitizers. Primary inputs included structured interviews with clinical investigators, procurement leaders at hospitals and clinics, and research scientists involved in translational photomedicine, complemented by expert consultations with regulatory specialists to validate interpretation of approval pathways. Secondary analysis encompassed peer-reviewed literature, clinical trial registries, patent landscapes, and publicly available regulatory communications to contextualize scientific advances and to triangulate timelines for clinical translation.

Data synthesis employed thematic analysis to identify recurrent technology trends, cross-referencing clinical workflows and procurement practices to surface adoption barriers and enablers. Quality assurance steps included cross-validation of interview-derived insights against published clinical outcomes and device specifications, while methodological limitations were documented to delineate confidence levels for interpretive conclusions. Throughout, emphasis was placed on transparency in assumptions and on clarifying evidence sources that underpin strategic recommendations.

Synthesis of how multidisciplinary collaboration, evidence generation, and operational alignment determine the path to clinical impact and sustainable adoption

In closing, photosensitizers occupy a distinctive niche at the intersection of chemistry, optics, and clinical practice, with meaningful implications for oncology, dermatology, and ophthalmology. Technological progress in molecular design and light-delivery systems is broadening clinical applicability, while evolving care models and procurement practices are shaping how new therapies are implemented across outpatient and hospital settings. Stakeholders that integrate robust translational pipelines, resilient supply chains, and regionally attuned commercialization strategies will be best positioned to convert scientific advances into durable clinical impact.

Ultimately, success in this domain hinges on multidisciplinary collaboration, high-quality clinical evidence, and adaptive commercial approaches that respect local regulatory and reimbursement realities. By aligning product attributes with clinical workflow needs and by proactively addressing supply and operational constraints, organizations can accelerate adoption and deliver tangible benefits to patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malignancy Photosensitizers Market, by Molecule Type

  • 8.1. Chlorin
  • 8.2. Cyanine
  • 8.3. Phthalocyanine
  • 8.4. Porphyrin

9. Malignancy Photosensitizers Market, by Light Source

  • 9.1. Laser
    • 9.1.1. Diode Laser
    • 9.1.2. Gas Laser
  • 9.2. Led
    • 9.2.1. Near Infrared Led
    • 9.2.2. Visible Led

10. Malignancy Photosensitizers Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Malignancy Photosensitizers Market, by Administration Route

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Topical

12. Malignancy Photosensitizers Market, by Application

  • 12.1. Dermatology
  • 12.2. Oncology
    • 12.2.1. Head And Neck Cancer
    • 12.2.2. Internal Organ Cancer
    • 12.2.3. Skin Cancer
  • 12.3. Ophthalmology

13. Malignancy Photosensitizers Market, by End User

  • 13.1. Clinic
    • 13.1.1. Outpatient Clinic
    • 13.1.2. Specialty Clinic
  • 13.2. Hospital
    • 13.2.1. Private Hospital
    • 13.2.2. Public Hospital
  • 13.3. Research Institute

14. Malignancy Photosensitizers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Malignancy Photosensitizers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Malignancy Photosensitizers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Malignancy Photosensitizers Market

18. China Malignancy Photosensitizers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bausch Health Co Ltd.
  • 19.6. Biolitec Pharma GmbH
  • 19.7. Endocyte, Inc.
  • 19.8. Galderma S.A.
  • 19.9. Merck KGaA
  • 19.10. Photocure ASA
  • 19.11. PhotoThera, Inc.
  • 19.12. QLT Inc.
  • 19.13. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • 19.14. Sorrento Therapeutics, Inc.
  • 19.15. Zhejiang Kangyuan Biopharm Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CHLORIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CHLORIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CHLORIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CYANINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CYANINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CYANINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PHTHALOCYANINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PHTHALOCYANINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PHTHALOCYANINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PORPHYRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PORPHYRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PORPHYRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY GAS LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY GAS LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY GAS LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY NEAR INFRARED LED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY NEAR INFRARED LED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY NEAR INFRARED LED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY VISIBLE LED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY VISIBLE LED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY VISIBLE LED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTERNAL ORGAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTERNAL ORGAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY INTERNAL ORGAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SKIN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SKIN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LIGHT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY LED, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MALIGNANCY PHOTOSENSITIZERS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)